SK Life Science (United States)

Recent papers from SK Life Science (United States)

1. A patenting perspective of IKZF2 molecular glue degraders (2020-present)Expert Opinion on Therapeutic Patents · 2026
2. Narrative Review: Efficacy, Safety, and Tolerability of Newer Third-Generation Antiseizure Medications for Focal Epilepsy: A New Benchmark in Treatment Outcomes?Neurology and Therapy · 2026
3. Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian populationEpilepsia · 2026
4. Impact of Zero Seizures on Healthcare Resource Utilization Among Cenobamate Patients (P1-11.010)Neurology · 2026
5. The “Hope, Hesitancy, and Hard Truths” Survey: A Patient and Provider Perspective on Epilepsy Treatment (P11-11.002)Neurology · 2026
6. Epilepsy-related and All-cause Healthcare Resource Utilization After Initiation of Adjunctive Cenobamate (P1-11.002)Neurology · 2026
7. Mortality Risk After Initiation of Cenobamate or Other Antiseizure Medications (P3-10.008)Neurology · 2026
8. Cenobamate in Adolescent Patients With Focal Epilepsy: A Phase 1 Pharmacokinetic Study to Determine an Appropriate Dosing Regimen to Optimize Safety, Tolerability, and Efficacy (P10-11.003)Neurology · 2026
9. Long-term Efficacy of Adjunctive Cenobamate: Open-label Extension of a Randomized Clinical Study in a Multinational Asian Population (P11-10.005)Neurology · 2026
10. Efficacy and Safety of Adjunctive Cenobamate for the Treatment of Primary Generalized Tonic-clonic Seizures in Adults and Adolescents (P3-10.003)Neurology · 2026
11. Delayed and Deferred Surgery Associated with Cenobamate Use in People with Drug Resistant Focal Epilepsy (P6-11.002)Neurology · 2026
12. Abstract 5790: Next-generation PRMT5 activity modulation through directed degradationCancer Research · 2026
13. Delayed and deferred surgery associated with cenobamate use in people with drug‐resistant focal epilepsyEpilepsia · 2026
14. Wide range of cenobamate doses associated with initial seizure freedom in patients with uncontrolled focal seizures: Post-hoc analysis of a phase 3, multicenter, open-label studyEpilepsy & Behavior · 2025
15. Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian populationEpilepsia · 2025
16. Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian populationEpilepsia · 2025
17. Exploration of the mechanism of action of cenobamateSeizure · 2025
18. A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizuresEpilepsia · 2025
19. The Cardiac Sodium Channel Safety Profile of Cenobamate at Therapeutic Concentrations: In Vitro AnalysesClinical and Translational Science · 2025
20. Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers2025